STUDY OF BMS-247550 IN PATIENTS WITH CANCER OF THE HEAD AND NECK

BMS-247550 在头颈癌患者中的研究

• 批准号: 7376321
• 负责人: Jill Gilbert
• 金额: $ 0.02万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376321
• 关键词: STUDY; BMS; 247550; PATIENTS; CANCER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Standard therapy for advanced cancer of the head and neck is to give chemotherapy. There are a number of chemotherapy drugs which can shrink head and neck cancers, unfortunately they control the disease only in some patients, and not permanently. For this reason, more effective treatments are needed. This research is being done because there is evidence from early clinical studies in humans and from animal studies, that a new kind of chemotherapy drug may be effective even when more standard drugs do not work well. BMS-247550 is an experimental chemotherapy drug that is similar to a parent drug called Epothilone B. The purpose of this study is to find out whether BMS-247550 is effective against this type of head and neck cancer, and also to find out what kinds of side effects the drug will have on patients.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。晚期头颈部癌症的标准治疗方法是进行化疗。有许多化疗药物可以缩小头颈部癌症，不幸的是，它们只控制了一些患者的疾病，而不是永久性的。为此，需要更有效的治疗方法。之所以进行这项研究，是因为有来自人类和动物的早期临床研究的证据表明，即使更多的标准药物效果不佳，一种新型化疗药物也可能有效。BMS-247550是一种实验性化疗药物，类似于母药Epothilone B。本研究的目的是了解BMS-247550是否对这种类型的头颈癌有效，并了解该药物对患者会有什么样的副作用。